Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms
Condition(s) studied
Investigational drug(s) / intervention(s)
calisda: Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU). calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months.
Study summary
The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.
The main questions it aims to answer are:
* Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
* Are the positive effects of calisda already noticeable after three months?
Researchers will compare two groups:
* Intervention group: Participants use the calisda intervention and continue their usual treatment.
* Control group: Participants continue with their usual treatment only.
Participants will:
* Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
* Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)
Eligibility
Primary outcome measure(s)
- 29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score — 6 months
The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| GAIA AG | Hamburg | Germany |
More Gaia AG trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07947095 on ClinicalTrials.gov ↗ ← All trials in Germany